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Pancreatic cancer is a devastating disease with dismal prognosis. The tumor
microenvironment is composed by multiple cell types, molecular factors, and extracellular
matrix forming a strong desmoplastic reaction, which is a hallmark of the disease. A
complex cross-talk between tumor cells and the stroma exists with reciprocal influence
that dictates tumor progression and ultimately the clinical outcome. In this context,
tumor infiltrating immune cells through secretion of chemokine and cytokines exert an
important regulatory role. Here we review the correlation between the immune infiltrates,
evaluated on tumor samples of pancreatic cancer patients underwent surgical resection,
and disease free and/or overall survival after surgery. Specifically, we focus on tumor
infiltrating lymphocytes (TILs), mast cells (MCs) and macrophages that all contribute to
a Th2-type inflammatory and immunosuppressive microenvironment. In these patients
tumor immune infiltrates not only do not contribute to disease eradication but rather the
features of Th2-type inflammation and immunosuppression is significantly associated with
more rapid disease progression and reduced survival.
Keywords: pancreatic cancer, tumor infiltrating lymphocytes, macrophages, mast cells, survival predictive factor,
univariate and multivariate analyses
INTRODUCTION
A relationship between tumors and immune system exists
(Schreiber et al., 2011). Indeed, multistep carcinogenesis results
from a cross-talk between cancer-cell-intrinsic factors and host
immune system (cell-extrinsic) effects (Zitvogel et al., 2006). This
cross-talk leads to different outcomes that are well explained by
the concept of the three Es of cancer immunoediting (Dunn
et al., 2004). At early stages immunosurveillance is responsi-
ble for tumor rejection (Elimination phase), in advanced stages
the immune system prevents tumor outgrowth and edits tumor
immunogenicity (Equilibrium phase) with the appearance in late
stages of tumor cell variants that are no longer recognized by the
immune system but rather tumors develop strategies to redirect
infiltrating immune cells toward a pro-tumorigenic phenotype
(Escape phase) (Dunn et al., 2004; Schreiber et al., 2011). The
mechanisms of immune escape have been recently recognized
(Hanahan and Weinberg, 2011; Hanahan and Coussens, 2012) as
an emerging hallmark of cancer.
Tumors are complex organs composed by tumor cells as well
as a variety of cells and factors forming the tumor microen-
vironment. Cells present in the tumor microenvironment are
cancer associated fibroblasts (CAFs), endothelial cells, pericytes
and immune cells, among which macrophages, dendritic cells
(DCs), natural killer cells, mast cells (MCs), granulocytes, B
Abbreviations: CAFs, cancer associated fibroblasts; DCs, dendritic cells; FRβ,
folate receptor β; LNs, lymph nodes; MCs, mast cells; PanIN, precursor lesions;
PDAC, pancreatic ductal adenocarcinoma; TAMs, tumor associated macrophages;
TILs, tumor infiltrating lymphocytes; Tregs, T regulatory cells; TSLP, thymic
stromal lymphopoietin.
cells and naïve and memory T cells [including cytotoxic CD8+
T cells and different subsets of CD4+ T and regulatory T cells
(Tregs)]. All these cell types and their released factors inter-
act with each other and determine the cytokine/chemokine
milieu, which ultimately have an impact on tumor regression or
progression.
Studies in several tumors have evaluated the association
between anti-tumor immunity and cancer prognosis but only
in recent years the development of more accurate methods for
analysis of immune infiltrates has allowed the identification of
the features of productive anti-tumor immunity (Fridman et al.,
2011). Large-scale studies have then revealed the prognostic and
predictive impact of immune infiltrates (Pages et al., 2005; Galon
et al., 2006; Denkert et al., 2010) and international efforts have
been put together to standardize predictive immune scores for
prognosis in several tumor histotypes (Galon et al., 2012).
Pancreatic ductal adenocarcinoma (PDAC) is a very aggres-
sive disease with dismal prognosis (Hidalgo, 2010). The tumor
microenvironment is characterized by a strong desmoplastic reac-
tion, which is a hallmark of the disease and it is believed to play a
role in carcinogenesis and in tumor progression through its effects
on angiogenesis, resistance to therapy and metastatic spread of
tumor cells (Kleeff et al., 2007; Erkan et al., 2012). Fibrosis is due
to activation by tumor and immune cells of pancreatic stellate
cells, which are responsible for extracellular matrix deposition.
Importantly, fibrogenesis is differentially regulated by Th1 (i.e.,
IFN-γ) and Th2 (i.e., IL-4, IL-5, and IL-13) cytokines, which exert
opposing roles by promoting collagen degradation and synthe-
sis, respectively (Wynn, 2004). Th1 or Th2 polarized immune
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cells may thus differentially contribute to fibrosis in PDAC and
possibly influence tumor progression.
The role of immune cells in pancreatic cancer development
and progression has been discussed elsewhere (Clark et al., 2009;
Evans and Costello, 2012; Wachsmann et al., 2012; Vonderheide
and Bayne, 2013). We refer readers interested in exhaustive sum-
maries of the field to those reviews. We focus here on studies in
human samples in which a correlation between immune infil-
trates and clinicopathologic features of PDAC that have prog-
nostic significance and an impact on patients’ survival has been
documented. These studies are summarized in Table 1.
TUMOR INFILTRATING LYMPHOCYTES
Tumor infiltrating lymphocytes (TILs) are present in several solid
tumors and key features such as their distribution, density, and
Table 1 | Tumor infiltrating immune cells as predictors of the clinical
outcome after surgery in pancreatic cancer patients.
Immune cells
in the tumor
Predictive marker of
favorable clinical outcome
References
T cells High CD4/8(+/+) countsa Fukunaga et al., 2004
CD4+high/CD8+high countsb Ino et al., 2013
GATA-3+/T-bet+ TILs ratio
below the median valuec
De Monte et al., 2011
CD4+high/CD8+high/%Treglow
countsd
Ino et al., 2013
Mast cells Low countse Strouch et al., 2010
Low counts in the intratumor
border zonef
Cai et al., 2011
Counts below the MCs scoreg Chang et al., 2011
Macrophages Low CD163+/CD204+ cells
infiltrationh
Kurahara et al., 2011
Low FRβ+ macrophages
infiltrationi
Kurahara et al., 2012
Low M2 macrophages
(CD163+/CD204+ cells)
infiltrationj
Ino et al., 2013
aT cell counts were considered high for CD4+ ≥ 20 and CD8+ ≥ 100, corre-
sponding to average numbers of 5 fields.
bHigh and low are based on the median values of CD4+ and CD8+ T cell counts.
cPatients were categorized in two groups based on the median value of the ratio
of the percentage of GATA-3+/T-bet+ TILs.
dPatients were categorized based on the average values of CD4+ T cells and
CD8+ T cell counts and of the percentage of Tregs.
eMCs counts were defined low if <8 and high if >13.
f Patients were categorized in two groups based on the median values of MCs
counts.
gMCs score was set at 3.68 and it was defined as the ratio of the number of
MCs to the percentage of CD45+ cells.
hFour grade infiltrations were considered: weak (<20/mm2), moderate
(>20<40/mm2), strong (>40<60/mm2), and massive (>60/mm2). Low corre-
spond to weak plus moderate; high correspond to strong plus massive.
iPatients were categorized in two groups based on the median values of FRβ+
macrophages counts.
jPatients were categorized in two groups based on the median values M2
macrophages counts.
function dictate their anti-versus pro-tumor activity (Galon et al.,
2006; Fridman et al., 2011, 2012). The major anti-tumor effec-
tors are memory (CD45RO+) cytotoxic CD8+ T cells while more
complex is the role of CD4+ T cells that depends on the pattern
of cytokines produced. Several CD4+ T cell subsets have been
described (Ruffell et al., 2010; Zhu et al., 2010): Th1 producing
IFN-γ, Th2 producing IL-4, IL-5 and IL-13, Th17 producing IL-
17, Th22 producing IL-22 and immunosuppressive Tregs. The
role of the different subsets in tumor immunity is still under
debate (Kennedy and Celis, 2008; Ruffell et al., 2010; Fridman
et al., 2012).
In PDAC few studies have addressed the role of TILs in anti-
tumor or pro-tumor activity and the correlation between those
infiltrates and the clinical outcome.
The presence of TILs in PDAC was first reported in a study
(Ademmer et al., 1998), which found that lymphocytes were typ-
ically localized as aggregates in the fibrotic interstitial tissue while
very few cells reached the epithelial tumor cells. The amount
of CD4+ and CD8+ T cells was variable among samples and
showed a predominant CD45RO+ memory phenotype. Only few
T cells were found in normal pancreatic tissue. Kalthoff and col-
laborators (Von Bernstorff et al., 2001) confirmed that TILs do
not reach tumor cells in significant numbers, being “trapped”
in the peritumoral tissue. Heterogeneous TILs distribution with
both focal areas of high accumulation, mainly at the periphery of
the tumor, and areas with diffusely scattered cells was reported
in (Ryschich et al., 2005). In this study a survival analysis per-
formed on 24 patients showed that median survival of patients
with high density of CD8+ T cells was, although not statisti-
cally significant, considerably higher than that of the group with
low CD8+ T cells density. Statistical significance was reached
in Fukunaga et al. (2004), in which 80 patients were analyzed.
The overall survival rate was significantly longer in patients with
CD8+ but not CD4+ T cell infiltration and highest for patients
positive for both T cells populations CD8/CD4(+/+) (positivity
was defined as average counts from 5 fields ≥100 for CD8 and
≥20 for CD4). Interestingly, the Authors found a negative corre-
lation between CD8/CD4(+/+) infiltration and both tumor depth
and TNM stage and in multivariate analysis the CD8/CD4(+/+)
infiltration was confirmed as an independent prognostic factor of
survival.
The presence of FoxP3+CD4+CD25+ T regulatory cells
(Tregs) possibly with immunosuppressive activity was evalu-
ated in tumor tissues, inflammatory tissue and draining lymph
nodes (LNs) in 198 PDAC patients and 15 patients with non-
neoplastic lesions (Hiraoka et al., 2006). Tregs infiltration was
localized in cancer stroma in areas of invasion. The prevalence
of Tregs was significantly higher in PDAC than in inflamma-
tory areas and in non-neoplastic lesions while no differences
were observed in the LNs. When patients were divided into
two groups based on values higher and lower than the aver-
age, the low Tregs group showed significantly better survival
than the high Tregs group did. The Authors analyzed Tregs also
in precursors lesions (PanIN) and interestingly found a sig-
nificant increase of Tregs prevalence during progression from
low-grade PanIN to invasive carcinoma (Hiraoka et al., 2006).
In the same study intraepithelial CD8+ T cells inversely cor-
related with Tregs infiltration in the stroma: indeed they were
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present in PanIN-1, significantly decreased in PanIN-2 and dras-
tically diminished to few in PanIN-3. More recently, in a large
retrospective study of 212 tumor samples, the same Authors (Ino
et al., 2013) reported that in multivariate analysis the prevalence
of tumor infiltrating CD4+ Thigh/CD8+ Thigh/%Treglow signifi-
cantly correlated with longer survival and had a higher hazard
ratio.
The characterization of TILs polarization in PDAC was ini-
tially reported in (Tassi et al., 2008), in which the presence
of Th2, Th1 and Tregs cells in tumor samples was evaluated
by immunohistochemistry using specific antibodies for GATA-
3 (i.e., to detect Th2 cells), T-bet (i.e., to detect Th1 cells) and
FoxP3. In this study PDAC patients undergoing surgery had cir-
culating carcinoembryonic antigen-specific CD4+ Th2 cells in
the presence of conserved anti-viral Th1 immunity. Furthermore,
analysis of TILs in tumor samples from the same patients showed
that, in agreement with the data in the blood, the number
of lymphoid cells expressing GATA-3 was significantly supe-
rior to that of lymphoid cells expressing T-bet. FoxP3 was also
expressed in lymphoid cells, as previously reported (Hiraoka
et al., 2006), and cells expressing FoxP3 were in greater pro-
portion relative to T-bet but in lower proportion relative to
GATA-3. More recently, we analyzed 69 tumor samples and found
that the amount of TILs differed among the samples and that
in all but one case the percentage of GATA-3+ was signifi-
cantly higher than that of T-bet+ TILs (De Monte et al., 2011).
To compare samples with different amounts of TILs we used
the ratio of the percentage of GATA-3+/T-bet+ TILs and per-
formed survival analysis. We found that patients with a ratio
inferior to the median value had a statistically prolonged survival.
Multivariate analysis stratifying for tumor stage, grading, size,
site, patient performance status, gender, age, surgical resection
margins, postoperative CA19.9 value, and postoperative treat-
ment confirmed that the ratio was independently predictive of
both disease-free and overall survival. We also identified a com-
plex cross-talk among tumor cells, CAFs and DCs that implicates
(i) the secretion of pro-inflammatory cytokines (i.e., TNF-α and
IL-1β) by tumor cells with (ii) activation of CAFs to secrete the
thymic stromal lymphopoietin (TSLP), (iii) activation by CAFs-
derived TSLP of resident DCs with Th2 polarizing capability
and which secrete Th2 attracting chemokines, and (iv) migra-
tion of TSLP activated DCs, possibly tumor antigen-loaded, to
draining LNs where Th2 cell priming occurs. Interestingly, epithe-
lial cells derived TSLP was also correlated with the presence of
Th2 inflammation in breast carcinoma (Pedroza-Gonzalez et al.,
2011).
Collectively, intraepithelial CD8+ T cells infiltration is
very rare in PDAC. CD4+ and CD8+ T cells are predom-
inantly present in the stroma either dispersed or in aggre-
gates, mainly at the periphery of the tumor. The prevalence
of CD4+ Thigh/CD8+ Thigh/%Treglow and the ratio of the
percentage of GATA-3+/T-bet+ TILs in the tumor stroma
were found to be independent predictive factors of over-
all survival after surgery in PDAC patients. An open issue
remains as to the antigen-specificity of tumor infiltrating
T cells.
MAST CELLS
MCs have been extensively studied for their role in allergic and
anaphylactic reactions during which FcεRI aggregation leads to
degranulation and release of multiplemediators (Galli et al., 2005,
2008). They are also known to be critical players in inflammatory
diseases where they act through “selective” release of mediators
without degranulation (Theoharides et al., 2007).
MCs infiltration is a relevant component of the tumor
microenvironment in a number of human malignancies
(Theoharides et al., 2007). MCs accumulate in the tumor stroma
in response to tumor-derived chemoattractants such as MCP-1
and RANTES. However, there is no general agreement on their
role in cancer. Indeed, MCs counts were shown to correlate
with either favorable or poor prognosis depending on the tumor
(Theoharides and Conti, 2004; Khazaie et al., 2011; Ribatti
and Crivellato, 2012). MCs can exert pro-tumorigenic effects
by secreting factors like VEGF and IL-8 that promote tumor
angiogenesis, tumor growth factors (i.e., PDGF, NGF, SCF)
and proteases that facilitate metastases. On the other hand,
high MCs counts in draining LNs were found to correlate with
better prognosis in human breast cancer where a mechanism
involving allergy-like degranulation with inhibitory effects on
tumor cell growth was hypothesized (Theoharides and Conti,
2004). This dual role is tentatively explained with their differ-
ent mechanisms of secretion: inflammation-driven selective
secretion is pro-tumorigenic while allergy-like degranulation is
anti-tumor.
In PDAC MCs were found in significant higher numbers in
tumor tissue compared to normal pancreas (Esposito et al., 2002).
MCs were located around ducts, blood vessels and nerves in the
connective tissue without particular clustering around neoplas-
tic cells. In a more extensive analysis of 137 patients, the same
Authors (Esposito et al., 2004) also showed that MCs number
correlated with the presence of LNs metastases and intratumor
microvessel density. Moreover, patients with low numbers of infil-
trating MCs compared with those with high numbers had a
tendency toward a longer survival.
More recently, a study (Strouch et al., 2010) on 53 tumor
specimens found that increased MCs infiltration correlated
with higher-grade tumors. Recurrence-free and disease-specific
survival was found significantly worse in patients with high
MCs counts compared to those with low counts. Interestingly,
patients with PDAC had higher serum tryptase activity than
patients with benign disease. Furthermore, in vitro exper-
iments using cell lines demonstrated a cross-talk between
tumor cells that secrete MCs attracting factor(s) and MCs,
which in turn release cancer cell growth and pro-invasive
factor(s).
Particular attention to MCs distribution in different tumor
areas was the focus of a study (Cai et al., 2011), which evaluated
in 103 patients MCs infiltration in intratumoral and peritumoral
areas and further in their border and center zones. In this correla-
tive study the Authors found that in the intratumoral border zone,
but not in the peritumoral or in the intratumoral center zone,
high MCs counts were associated with LNs metastasis, tumor
stage, lymphatic, and microvascular invasion. Significantly, high
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intratumoral border zone infiltration was identified as an inde-
pendent prognostic factor of overall survival in resected patients,
underlying the relevance of zone-specific distribution of MCs
in PDAC.
HighMCs infiltration was further confirmed as a negative pre-
dictive marker of survival in another study (Chang et al., 2011),
which comprised 67 tumor samples. However, in multivariate
analysis the MCs score used to stratify the patients did not reach
statistical significance.
Collectively, the number of infiltrating MCs was found
increased in PDAC compared to normal pancreas. A correlation
between increased MCs numbers and the presence of LNs metas-
tasis, tumor grade, intratumormicrovessel density, and lymphatic
and microvascular invasion was observed. The degree of MCs
infiltration was identified as a predictive marker of patients’
survival in the majority of studies.
MACROPHAGES
Solid tumors are frequently infiltrated by tumor-associated
macrophages (TAMs), which are driven by tumor and T cell
derived cytokines (especially IL-4, IL-10, and IL-13) to acquire
an “alternatively activated” M2 phenotype with pro-tumor prop-
erties (Mantovani et al., 2002; Gordon, 2003). This M2-type
macrophages are opposed to the “classic” M1-type that are acti-
vated by Th1 cytokines (IFN-γ, IL-1β) and are endowed with
anti-tumor properties (Lewis and Pollard, 2006). TAMs receive
signals from diverse cells within the tumor microenvironment
and promote tumor growth and progression through regulation
of angiogenesis, production of soluble mediators, which support
proliferation, survival and invasive properties of tumor cells, and
direct and indirect immunosuppression/modulation of lymphoid
cells function (Mantovani et al., 2002; Qian and Pollard, 2010;
Balkwill and Mantovani, 2012; Ruffell et al., 2012).
CD68+ cells were found increased in PDAC compared
to normal pancreatic tissue: however, in 137 tumor sam-
ples no significant correlation with cumulative survival was
demonstrated (Esposito et al., 2004). A more accurate analy-
sis of TAM polarization was performed on 76 patients sam-
ples by immunohistochemistry using both anti-CD68 (i.e.,
pan macrophage) and anti-CD163 and anti-CD204 antibodies
(i.e., which should preferentially stain M2-type macrophages)
(Kurahara et al., 2011). The number of CD68+ cells varied
among the samples examined: some tumors were extensively
infiltrated while others had only sparse CD68+ cells infil-
tration. CD163+ and CD204+ cells were present within the
same areas and the counts were lower than the number of
total CD68+ cells. Interestingly, the number of CD163+ and
CD204+ better then CD68+ cells correlated with LNs metas-
tasis (Kurahara et al., 2011). Patients were stratified into two
groups based on mean values of CD68+ or CD163+/CD204+
cell counts. The Authors found that lymphatic vessel den-
sity in the invasive front was significantly higher for high
CD163+/CD204+ tumor samples compared to low samples
but not statistically significant difference was found between
the high and low CD68+ infiltration. The data suggests that
increased M2-type infiltration in the invasive front might have
a role in lymph-angiogenesis and lymphatic metastatic spread
in PDAC. When the prognostic impact of TAMs infiltration
was assessed, the prognosis was significantly poorer in the
high CD163+/CD204+ group compared with the low. Whereas,
although the high CD68+ tended to have a poor prognosis
compared with the low CD68+, no significant difference in the
survival rate between the high and low CD68+ cell counts was
found.
In a following study (Kurahara et al., 2013), the same Authors
showed a strong association among the density of VEGF-C
expressingM2-type TAMs in regional LNs, nodal lymphatic vessel
density and the incidence of isolated tumor cells in pN0 pan-
creatic cancer, further suggesting that M2-polarized TAMs may
indeed facilitate nodal lymph-angiogenesis and promote lymph
nodes micro-metastases.
Infiltration of macrophages that express the folate receptor β
(FRβ) [i.e., a marker expressed in M2-type macrophages (Puig-
Kroger et al., 2009)] was also investigated in PDAC (Kurahara
et al., 2012). FRβ+ macrophages were prominent in perivascu-
lar areas of the tumor invasive front and when in high numbers
they showed (i) a positive association with high tumor micro-
vessel density, (ii) a high incidence of hematogenous metastasis,
and (iii) poor prognosis in PDAC patients (Kurahara et al., 2012).
In agreement with an inverse correlation between M2-type
TAMs infiltration and disease survival, a recent study (Ino et al.,
2013), which included 212 patients, reported that high CD163+
and CD204+ cells infiltration was significantly associated with
both shorter disease-free and overall survival. In the same study
the presence of M2-type macrophages and the percentage of Tregs
correlated with the presence of venous invasion.
Another study (Tjomsland et al., 2011) evaluated macrophage
infiltration in PDAC samples by CD68 and CD163 gene expres-
sion analysis and found that, in contrast with the studies reported
above, high CD163 expression correlated with longer survival.
However, clinical correlation was done in a limited number
of samples (30 patients) compared to the ones reported above
(Kurahara et al., 2011, 2012, 2013; Ino et al., 2013) and based on
CD163 gene expression rather then actual macrophage counts.
Collectively, higher numbers of CD68+ cells were found in
PDAC samples compared to normal pancreas. Functional polar-
ization toward M2-type correlates with a poor prognosis after
surgery in resected patients. High CD163+ and CD204+ cell
counts in perivascular areas of the tumor invasive front corre-
late with lymphangiogensis, high tumor micro-vessel density, LNs
occult metastasis and poor prognosis in PDAC patients.
CONCLUDING REMARKS
Several studies have demonstrated that tumor antigens specific
T cells are present in the circulation of PDAC patients (Laheru
and Jaffee, 2005). However, the presence of a Th2-type inflamma-
tory and immunosuppressive microenvironment questions the
possibility that anti-tumor Th1 effectors reach the tumor and
eventually maintain their effector functions. Future therapeu-
tic approaches in PDAC should implement the efficacy of Th1
effectors by a combination of active and adoptive immunother-
apy (Mellman et al., 2011) and strategies, such as the use of
immunomodulators and/or therapy with agonistic CD40 that has
proved to be efficacious in PDAC patients (Beatty et al., 2011),
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aimed at redirecting Th2 toward Th1-type inflammation in the
tumor microenvironment. Moreover, since extensive immuno-
histochemical evaluations in bioptic material are not feasible, it
will be interesting to compare the results of the studies reported
here in surgical specimens from patients undergoing neoadjuvant
therapies such as chemo or immunotherapy.
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